HERITAGE: a phase III safety and efficacy trial of the proposed trastuzumab biosimilar Myl-1401O versus herceptin. (February 2017) - Rugo, H.; Barve, A.; Waller, C.; Bronchud, M.H.; Herson, J.; Yuan, J.; Manikhas, A.; Bondarenko, I.; Mukhametshina, G.; Nemsadze, G.; Parra, J.; Abesamis Tiambeng, M.L.; et al.